NeurAxis, a medical tech company specializing in neuromodulation therapies, will release its third quarter 2026 financial results on November 9, 2026, before the market opens. The company will host a conference call at 9:00 am ET the same day to discuss the results. NeurAxis focuses on its FDA-cleared IB-Stim device for treating functional abdominal pain and is conducting further clinical trials for other conditions. This update is important for investors tracking the company's progress and commercial growth.
NeurAxis's upcoming third quarter 2026 results and business update call are scheduled for November 9, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 27, 2026 17:43 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 69 rose and 68 fell today. Notable movers include ENVB at USD 1.41 with a 1-day change of +2.17%, XRAY at USD 9.42 with a 1-day change of +2.17% and 100% buy order activity, and BKD at USD 9.55 with a 1-day change of -2.15%.
Black Ore introduced Black Ore for Small Firms, an AI-powered tax automation platform designed for small to mid-sized accounting practices. It integrates with Intuit tax software, enabling firms to handle more clients without increasing staff by auto...
Alm. Brand A/S executed a share buy-back program from October 20 to 26, 2026, purchasing 1.81 million shares at an average price of DKK 17.41 each. This brings the total shares bought under the program to nearly 19.58 million, costing about DKK 324 m...
Hyphenate, an autonomous finance platform, secured $45 million in Series A funding following an 86-fold revenue increase and an 11-fold growth in customers over 12 months. Its AI-driven agents now handle 90% of routine finance work, such as invoicing...
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
